Ronnebaum Sarah, Aly Abdalla, Patel Dipen, Benavente Fernando, Rueda Juan-David
OPEN Health, Bethesda, MD 20814, USA.
AstraZeneca, Gaithersburg, MD 20878, USA.
Hepat Oncol. 2021 Aug 26;9(1):HEP41. doi: 10.2217/hep-2021-0003. eCollection 2022 Mar.
To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.
MATERIALS & METHODS: Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.
From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.
Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.
识别并评估所有评估晚期肝细胞癌推荐治疗方法的试验的相似性。
系统检索了截至2021年2月任何时间发表的任何阶段的单臂试验和随机试验。
在审查的5677条记录中，有50项试验纳入审查，其中24项评估了相似性。在一线（1L）治疗中，与其他1L试验相比，几项评估索拉非尼的试验纳入了病情更严重和/或体能状态更差的患者；二线（2L）治疗中的试验总体相似。所有试验组的中位生存期均<2年。
评估推荐治疗方法的试验在很大程度上相似，适用于对几种疗效和安全性结果进行定量比较。
